NEW YORK – Invitae and Pacific Biosciences on Thursday announced a research collaboration that will use long-read next-generation sequencing to help develop diagnostic testing for epilepsy.
Under the terms of the deal, the firms will look for molecular targets and codevelop methods to support new diagnostic epilepsy tests. Invitae will also expand its PacBio sequencing capacity. Financial and other terms of the agreement were not disclosed.